Mesoblast (NASDAQ:MESO) Director Gregory George Buys 1,586,890 Shares

Mesoblast Limited (NASDAQ:MESO) Director Gregory George purchased 1,586,890 shares of Mesoblast stock in a transaction dated Thursday, April 9th. The stock was bought at an average cost of $1.44 per share, with a total value of $2,285,121.60. Following the completion of the purchase, the director owned 13,586,890 shares in the company, valued at approximately $19,565,121.60. This trade represents a 13.22% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Gregory George also recently made the following trade(s):

• On Friday, April 10th, Gregory George acquired 2,324,072 shares of Mesoblast stock. The shares were bought at an average price of $1.48 per share, for a total transaction of $3,439,626.56.
• On Thursday, April 9th, Gregory George bought 1,981,890 shares of Mesoblast stock. The shares were purchased at an average cost of $8.59 per share, for a total transaction of $17,024,435.10.
• On Saturday, April 4th, Gregory George purchased 4,000,000 shares of Mesoblast stock. The shares were purchased at an average cost of $1.42 per share, with a total value of $5,680,000.00.

Mesoblast Stock Down 2.0%

Shares of MESO stock opened at $14.70 on Tuesday. Mesoblast Limited has a 1 year low of $9.88 and a 1 year high of $21.50. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58. The business’s fifty day moving average is $15.60 and its 200-day moving average is $16.80. The stock has a market cap of $1.90 billion, a PE ratio of -27.22 and a beta of 2.19.

Mesoblast (NASDAQ:MESO) last released its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $25.67 million during the quarter. Equities analysts expect that Mesoblast Limited will post -0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Mesoblast

A number of institutional investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Mesoblast during the 4th quarter worth about $32,000. Quadrature Capital Ltd purchased a new position in shares of Mesoblast in the fourth quarter worth approximately $479,000. AQR Capital Management LLC raised its holdings in shares of Mesoblast by 80.5% during the fourth quarter. AQR Capital Management LLC now owns 25,215 shares of the company’s stock valued at $455,000 after acquiring an additional 11,242 shares during the period. &PARTNERS purchased a new stake in shares of Mesoblast in the 4th quarter valued at approximately $334,000. Finally, Opal Capital LLC acquired a new position in Mesoblast in the 4th quarter worth approximately $307,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Mesoblast in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.